川田　一郎 (カワダ　イチロウ)

ICHIRO Kawada

写真a

所属（所属キャンパス）

研究所・センター等 保健管理センター 慶應義塾大学医学部　呼吸器内科 （日吉）

職名

准教授（有期）

外部リンク
このページの先頭へ▲

経歴 【 表示 ／ 非表示 】

  • 1998年05月
    -
    2000年04月

    慶應義塾大学医学部, 内科学教室, 研修医

  • 2000年05月
    -
    2001年05月

    埼玉県立循環器・呼吸器病センター, 内科, 専修医

  • 2001年06月
    -
    2002年05月

    東京歯科大学市川総合病院, 内科, 助手

  • 2002年06月
    -
    2005年06月

    慶應義塾大学医学部, 呼吸循環器内科, 助手

  • 2005年07月
    -
    2009年12月

    日野市立病院, 内科, 主任医員

全件表示 >>

このページの先頭へ▲

学歴 【 表示 ／ 非表示 】

  • 1992年04月
    -
    1998年03月

    慶應義塾大学, 医学部

    大学, 卒業

このページの先頭へ▲

学位 【 表示 ／ 非表示 】

  • 学士（医学）, 慶應義塾大学, 課程, 1998年03月

  • 博士（医学）, 慶應義塾大学, 論文, 2009年02月

    非小細胞肺がん患者における上皮成長因子受容体遺伝子変異のRFLP法によるスクリーニング法の確立

このページの先頭へ▲

免許・資格 【 表示 ／ 非表示 】

  • 医師免許, 1998年05月

  • 日本内科学会 認定内科医, 2002年09月

  • 日本内科学会 総合内科専門医, 2006年12月

  • 日本内科学会 指導医, 2006年09月

  • 日本内科学会 JMECCインストラクター, 2015年12月

全件表示 >>

このページの先頭へ▲
 

研究分野 【 表示 ／ 非表示 】

  • ライフサイエンス / 呼吸器内科学

このページの先頭へ▲
 

著書 【 表示 ／ 非表示 】

  • インフルエンザ診療マニュアル

    金澤實, 川田一郎, 柳澤勉, 南江堂, 2001年01月

    担当範囲: インフルエンザと社会

このページの先頭へ▲

論文 【 表示 ／ 非表示 】

  • Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III Clinical Trial

    Shinkai M., Tsushima K., Tanaka S., Hagiwara E., Tarumoto N., Kawada I., Hirai Y., Fujiwara S., Komase Y., Saraya T., Koh H., Kagiyama N., Shimada M., Kanou D., Antoku S., Uchida Y., Tokue Y., Takamori M., Gon Y., Ie K., Yamazaki Y., Harada K., Miyao N., Naka T., Iwata M., Nakagawa A., Hiyama K., Ogawa Y., Shinoda M., Ota S., Hirouchi T., Terada J., Kawano S., Ogura T., Sakurai T., Matsumoto Y., Kunishima H., Kobayashi O., Iwata S.

    Infectious Diseases and Therapy （Infectious Diseases and Therapy)  10 （ 4 ） 2489 - 2509 2021年12月

    ISSN  21938229

    　概要を見る

    Introduction: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), is an enveloped, single-stranded RNA virus. Favipiravir is an orally administrable antiviral drug whose mechanism of action is to selectively inhibit RNA-dependent RNA polymerase. A preliminary trial in COVID-19 patients reported significant improvements across a multitude of clinical parameters, but these findings have not been confirmed in an adequate well-controlled trial. We conducted a randomized, single-blind, placebo-controlled Phase III trial assessing the efficacy and safety of favipiravir in patients with moderate pneumonia not requiring oxygen therapy. Methods: COVID-19 patients with moderate pneumonia (SpO2 ≥ 94%) within 10 days of onset of fever (temperature ≥ 37.5 °C) were assigned to receive either placebo or favipiravir (1800 mg twice a day on Day 1, followed by 800 mg twice a day for up to 13 days) in a ratio of 1:2. An adaptive design was used to re-estimate the sample size. The primary endpoint was a composite outcome defined as the time to improvement in temperature, oxygen saturation levels (SpO2), and findings on chest imaging, and recovery to SARS-CoV-2-negative. This endpoint was re-examined by the Central Committee under blinded conditions. Results: A total of 156 patients were randomized. The median time of the primary endpoint was 11.9 days in the favipiravir group and 14.7 days in the placebo group, with a significant difference (p = 0.0136). Favipiravir-treated patients with known risk factors such as obesity or coexisting conditions provided better effects. Furthermore, patients with early-onset in the favipiravir group showed higher odds ratio. No deaths were documented. Although adverse events in the favipiravir group were predominantly transient, the incidence was significantly higher. Conclusions: The results suggested favipiravir may be one of options for moderate COVID-19 pneumonia treatment. However, the risk of adverse events, including hyperuricemia, should be carefully considered. Trial registration: Clinicaltrials.jp number: JapicCTI-205238.

  • Unbiased, comprehensive analysis of Japanese health checkup data reveals a protective effect of light to moderate alcohol consumption on lung function

    Makino K., Shimizu-Hirota R., Goda N., Hashimoto M., Kawada I., Kashiwagi K., Hirota Y., Itoh H., Jinzaki M., Iwao Y., Ko M., Ko S., Takaishi H.

    Scientific Reports （Scientific Reports)  11 （ 1 ）  2021年12月

    　概要を見る

    The overall effect of lifestyle habits, such as alcohol consumption, on general health remains controversial and it is important to clarify how such habits affect aging-related health impairments. To discover novel impacts of lifestyle on general health, we employed a mathematical approach to perform a comprehensive, unbiased, cross-sectional analysis of data from 6036 subjects who participated in a Japanese health checkup. Notably, we found that moderate alcohol consumption was positively correlated with lung function, muscle mass, and strength. Health checkup data were collected periodically from the same subjects. These people were light to moderate drinkers who had high health awareness and were basically free of major underlying diseases. We next analyzed 5 years of data from 1765 of these subjects. We found that higher baseline alcohol consumption, as well as increased alcohol intake over 5 years attenuated time-related deterioration of forced vital capacity without affecting total lung volume. This effect was independent of smoking. Our study suggests a possible protective effect of moderate amounts of alcohol on lung function, due to increased muscle mass/strength and forced vital capacity.

  • Longitudinal Assessment of Prognostic Understanding in Patients with Advanced Lung Cancer and Its Association with Their Psychological Distress

    Arai D., Sato T., Nakachi I., Fujisawa D., Takeuchi M., Sato Y., Kawada I., Yasuda H., Ikemura S., Terai H., Nukaga S., Inoue T., Nakamura M., Oyamada Y., Terashima T., Sayama K., Saito F., Sakamaki F., Naoki K., Fukunaga K., Soejima K.

    Oncologist （Oncologist)  26 （ 12 ） e2265 - e2273 2021年12月

    ISSN  10837159

    　概要を見る

    Background: Accurate prognostic understanding in patients with advanced cancer is essential for shared decision making; however, patients may experience psychological burden through knowing the incurable nature of advanced cancer. It has been unclear how their prognostic understanding fluctuates and whether accurate prognostic understanding is associated with psychological distress from the time of diagnosis over time. Materials and Methods: We longitudinally investigated prognostic understanding in 225 patients with newly diagnosed advanced lung cancer at 16 hospitals in Japan until 24 months after diagnosis. We examined associated factors with being consistently accurate in prognostic understanding, especially focusing on its association with psychological well-being. Results: The proportion of patients with an inaccurate prognostic understanding remained approximately 20% over time with the presence of patients with inconsistent understanding. Patients with consistently accurate prognostic understanding showed a significantly lower Emotional Well-Being subscale score at both 3 and 6 months after diagnosis (p =.010 and p =.014, respectively). In multivariate analyses, being consistently accurate in prognostic understanding was significantly associated with female gender and higher lung cancer–specific symptom burden at 3 months (p =.008 and p =.005, respectively) and lower emotional well-being at 6 months (p =.006). Conclusion: Although substantial proportions of patients with advanced lung cancer had inaccurate prognostic understanding from the time of diagnosis over time, patients with consistently accurate prognostic understanding experienced greater psychological burden. Our findings highlight the importance of continuous psychological care and support for patients who understand their severe prognosis accurately. Implications for Practice: This study demonstrated that approximately 20% of patients with advanced lung cancer had an inaccurate understanding about their prognosis, not only at the time of diagnosis but also at the later time points. Being consistently accurate in prognostic understanding was significantly associated with elevated levels of psychological distress. Although accurate prognostic understanding is essential for decision making for treatment and advance care planning, health care providers should be aware of psychological burdens in patients that accept their severe prognosis accurately. Appropriate care and support for such patients are warranted from diagnosis over time.

  • Comprehensive and long-term surveys of COVID-19 sequelae in Japan, an ambidirectional multicentre cohort study: Study protocol

    Nakagawara K., Namkoong H., Terai H., Masaki K., Tanosaki T., Shimamoto K., Lee H., Tanaka H., Okamori S., Kabata H., Chubachi S., Ikemura S., Kamata H., Yasuda H., Kawada I., Ishii M., Ishibashi Y., Harada S., Fujita T., Ito D., Bun S., Tabuchi H., Kanzaki S., Shimizu E., Fukuda K., Yamagami J., Kobayashi K., Hirano T., Inoue T., Kagyo J., Shiomi T., Ohgino K., Sayama K., Otsuka K., Miyao N., Odani T., Oyamada Y., Masuzawa K., Nakayama S., Suzuki Y., Baba R., Nakachi I., Kuwahara N., Ishiguro T., Mashimo S., Minematsu N., Ueda S., Manabe T., Funatsu Y., Koh H., Yoshiyama T., Saito F., Ishioka K., Takahashi S., Nakamura M., Goto A., Harada N., Kusaka Y., Nakano Y., Nishio K., Tateno H., Edahiro R., Takeda Y., Kumanogoh A., Kodama N., Okamoto M., Umeda A., Hagimura K., Sato T., Miyazaki N., Takemura R., Sato Y., Takebayashi T., Nakahara J., Mimura M., Ogawa K., Shimmura S., Negishi K., Tsubota K., Amagai M., Goto R., Ibuka Y., Hasegawa N., Kitagawa Y., Kanai T., Fukunaga K.

    BMJ Open Respiratory Research （BMJ Open Respiratory Research)  8 （ 1 ）  2021年11月

    　概要を見る

    Introduction The rapid spread of COVID-19 posed a global burden. Substantial number of people died of the disease in the acute phase of infection. In addition, a significant proportion of patients have been reported to suffer from post-acute phase symptoms, sequelae of COVID-19, which may negatively influence the quality of daily living and/or socioeconomic circumstances of the patients. However, no previous study has comprehensively and objectively assessed the quality of life of patients by using existing international scales. Further, evidence of socioeconomic consequences among patients with COVID-19 is scarce. To address the multidimensional issues from sequelae of COVID-19, evidence from comprehensive surveys beyond clinical perspectives is critical that investigates health, and social determinants of disease progression as well as socioeconomic consequences at a large scale. Methods and analysis In this study, we plan to conduct a nationwide and comprehensive survey for the sequelae of COVID-19 in a total of 1000 patients diagnosed at 27 hospitals throughout Japan. This study will evaluate not only the health-related status of patients from clinical perspectives but also the Health-related Quality of Life (HRQoL) scores, socioeconomic status and consequences to discuss the sequelae of the disease and the related risk factors. The primary endpoint is the frequency of long-term complications of COVID-19 infection. The secondary endpoints are risk factors for progression to sequelae of COVID-19 infection. The study will provide robust and important evidence as a resource to tackle the issues from the sequelae of COVID-19 from the multi-dimensional perspectives. Ethics and dissemination This trial was approved by the Keio University School of Medicine Ethics Committee (20200243, UMIN000042299). The results of this study will be reported at a society meeting or published in a peer-reviewed journal.

  • Cardiac tamponade due to primary malignant pericardial mesothelioma diagnosed with surgical pericardial resection

    Kawakami N., Kawai M., Namkoong H., Arai D., Ueda S., Hamada K., Kawada I., Hasegawa N., Mikami S., Asamura H., Fukunaga K.

    Journal of Cardiology Cases （Journal of Cardiology Cases)  24 （ 4 ） 149 - 152 2021年10月

    　概要を見る

    Primary malignant pericardial mesothelioma is an extremely rare disease. Malignant disease of the pericardium is an infrequent cause of cardiac tamponade. Hence, cardiac tamponade in the context of primary malignant mesothelioma of the pericardium is an uncommon clinical scenario. A 67-year-old male patient, an ex-smoker, complaining of progressive lethargy was referred to a hospital for investigation of persistent pericardial effusion. The pericardial fluid cytology was categorized as class Ⅲ. Thereafter, he was referred to our hospital for further evaluation. Fluorodeoxyglucose (FDG) positron emission tomography (PET) revealed FDG accumulation in the pericardium and mediastinal lymph node. Surgical biopsy of the pericardium was performed through a subxiphoid approach for a definitive diagnosis. Histopathological examination revealed diffuse infiltration of the pericardium by a malignant tumor consisting of epithelioid cells with large round nuclei and prominent nucleoli, arranged in a tubular papillary pattern. Finally, the patient was diagnosed with primary malignant pericardial mesothelioma of epithelioid type. The patient died 6 weeks after admission. This diagnosis must be considered in patients having unexplained massive pericardial effusion. Furthermore, we should consider prompt cytological analysis and FDG PET to arrive rapidly at a definitive diagnosis to administer combination chemotherapy that may provide clinical benefit. <Learning objective: Primary malignant pericardial mesothelioma is a rare disease. Malignant disease of the pericardium is an infrequent cause of cardiac tamponade. Hence, cardiac tamponade in the context of primary malignant mesothelioma of the pericardium is an uncommon clinical scenario. However, this diagnosis must be considered in patients having unexplained massive pericardial effusion. Furthermore, we should consider prompt cytological analysis and fluorodeoxyglucose positron emission tomography to arrive rapidly at a definitive diagnosis to administer combination chemotherapy that may provide clinical benefit.>

全件表示 >>

このページの先頭へ▲

総説・解説等 【 表示 ／ 非表示 】

このページの先頭へ▲

研究発表 【 表示 ／ 非表示 】

  • NHBE肺癌発生モデルにおける癌抑制遺伝子、癌遺伝子のメチル化、および脱メチル化の定量的検討

    山口 佳寿博

    第44回日本肺癌学会総会 (東京) , 

    2003年11月
    , 

    口頭発表（一般）

  • DNAメチル転移酵素3b(DNMT3b)の癌化における重要性

    山口 佳寿博

    第44回日本肺癌学会総会 (東京) , 

    2003年11月
    , 

    口頭発表（一般）

  • 癌化いおけるde novo DNAメチル転移酵素、DNMT3b1/3b2の機能的差異の検討−実験モデルの確立−

    山口 佳寿博

    第44回日本肺癌学会総会 (東京) , 

    2003年11月
    , 

    口頭発表（一般）

  • 癌化におけるDNAメチルトランスフェラーゼ（DNMT3b）の重要性

    副島研造，川田一郎，渡邊秀生，藤島清太郎，山口佳寿博

    第43回日本呼吸器学会総会, 

    2003年03月
    , 

    口頭発表（一般）

  • NHBE肺癌発生モデルにおける癌抑制遺伝子および癌遺伝子プロモーター領域のメチル化，脱メチル化の検討

    川田一郎，副島研造，渡邊秀生，山口佳寿博

    43回日本呼吸器学会総会, 

    2003年03月
    , 

    口頭発表（一般）

全件表示 >>

このページの先頭へ▲

競争的研究費の研究課題 【 表示 ／ 非表示 】

  • 悪性胸膜中皮腫におけるMET遺伝子異常の解明と新薬の個別化治療への臨床応用

    2019年04月
    -
    2023年03月

    文部科学省・日本学術振興会, 科学研究費助成事業, 川田　一郎, 基盤研究（Ｃ）, 補助金,  研究代表者

このページの先頭へ▲

受賞 【 表示 ／ 非表示 】

  • 研究奨励賞(Respiratory Research Award)

    2014年11月, 第18回東京呼吸病態研究会, 非小細胞肺癌とMET遺伝子異常, RON遺伝子異常

    受賞区分： その他

このページの先頭へ▲
 

担当授業科目 【 表示 ／ 非表示 】

  • 内科学（呼吸器）講義

    2022年度

  • 内科学（呼吸器）講義

    2021年度

  • 内科学（呼吸器）講義

    2020年度

  • 内科学（呼吸器）講義

    2019年度

このページの先頭へ▲

担当経験のある授業科目 【 表示 ／ 非表示 】

  • 内科学、血液ガス、酸塩基平衡

    慶應義塾

    2015年04月
    -
    2016年03月
    , 

    秋学期, 講義

このページの先頭へ▲